2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 252-254
Treatment Considerations, Biological Therapies, Antibody Therapy, Adverse Events, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Infectious Diseases, Other Pathogens, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

467 Malaria counter-mutations in transfusion recipients with sickle cell anemia and blood donors with sickle cell trait in Uganda: Findings from the full assessment of clinical transfusion support (FACTS) study

Alexandra Power-Hays, MD, Kathryn McElhinney2, Abigail Kincaid, MS3, Charles Kato, MBChB4, Sadati Aliwuya5, Susan Stuber, MA6, Ruth Namazzi, MMED7, Teresa Smith Latham, DrPH8, Russell E E. Ware, MD, PhD9
1 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
2 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Global Health Uganda, Jinja, Uganda
5 Global Health Uganda, Jinja, Uganda
6 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 Makere University School of Medicine, Kampala, Uganda
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
9 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Introduction: The HBB sickle mutation protects against malaria with the heterozygous sickle cell trait (HbAS) conferring ~90% reduction in severe Plasmodium falciparum infection. Recent evidence suggests that P. falciparum is developing counter-mutations to evade the protection conferred by the sickle allele. Three non-synonymous single nucleotide polymorphisms (SNPs) in the malaria genome, termed P. falciparum sickle-associated (PFSA) variants 1, 2, and 3, were more prevalent in children with HbAS and severe malaria in Gambia and Kenya compared to children with HbAA (Band et al, Nature, 2022). These findings were replicated in children with HbAS and mild malaria in Ghana and asymptomatic parasitemia in Cameroon. Together, these studies confirm that PFSA+ variants decrease the protection associated with the heterozygous sickle allele, but whether these newly identified mutations affect children with homozygous sickle cell anemia (HbSS) is unknown.

Methods: Full Assessment of Clinical Transfusion Support (FACTS, NCT07094646) was a prospective study to determine the prevalence of HbSS and malaria in children receiving blood transfusions and their donated blood units at Jinja Regional Referral Hospital in Uganda, a region with ~20% sickle cell trait and >1.0% HbSS. After informed consent, dried blood spots (DBS) were made from all children needing a blood transfusion and from the transfused donor units. DBS samples were transported to Cincinnati Children’s Hospital and evaluated for the sickle allele (rs334) via TaqMan PCR and for Plasmodium and falciparum DNA via qPCR. Using custom probes, PFSA1+ and 2+ were detected via TaqMan qPCR; PFSA3+ was detected via nested PCR, with thermal Phusion Plus Taq optimized for AT-rich products followed by TaqMan qPCR. All PFSA variant controls were confirmed via Sanger sequencing.

Results: During 60 days of sample collection, 250 children received 297 transfusions. DBS from 135 children (54%) receiving transfusions had detectable P. falciparum, including 70 (52%) with HbSS, 62 (46%) with HbAA, and 3 (2%) with HbAS. The near absence of HbAS among children requiring transfusions for malaria confirms the strong protection of the sickle allele, while the overrepresentation of HbSS highlights its disproportionate transfusion burden due to severe anemia. All three PFSA+ variants were significantly more prevalent in malaria-positive DBS from children with HbSS compared to HbAA: the odds ratio (OR) for PFSA1+ was 11.8 (95% CI 4.7-29.4, p<0.0001), for PFSA2+ OR=3.2 (95% CI 1.4-7.4, p=0.006), and for PFSA3+ OR=15.2 (95% CI 5.5-41.5, p<0.0001). Excluding DBS samples with mixed P. falciparum infections, 34/46 children (74%) with HbSS and malaria carried all 3 PFSA+ mutations compared to only 6/26 (23%) with HbAA and malaria (OR=9.4, 95% CI 3.1-29.1, p=0.0001). Conversely, only 5/46 children (11%) with HbSS and malaria had no PFSA+ mutations, compared to 14/26 children (54%) with HbAA and malaria (OR=0.1, 95% CI 0.03-0.3, p=0.0002). All three PFSA+ mutations were detected from 3/3 children (100%) with HbAS and malaria who received transfusions. Among 293 donated blood units, 84 (29%) had detectable P. falciparum DNA; 62 (74%) of those were from HbAA donors while 22 (26%) were HbAS donors. PFSA1+ and PFSA3+ mutations were more common in HbAS donors than HbAA: PFSA1+ OR=7.8 (95% CI 2.1-29.2, p=0.002) and PFSA3+ OR=19.3 (3.9-97.5, p=0.0003). Every HbAS donated unit with P. falciparum parasitemia had at least one PFSA+ mutation.

Conclusions: A disproportionately high prevalence of PFSA+ malaria mutations exists in Ugandan children with sickle cell anemia receiving transfusions, and in blood donors with sickle cell trait compared to those with HbAA. Most (89%) children with HbSS and malaria requiring transfusion had at least one PFSA+ variant, and 74% had all three mutations These data suggest PFSA+ variants circumvent the biological protection provided by the sickle allele. Further, the presence of PFSA+ malaria in ~20% of donated blood units may increase transfusion-mediated transmission. Since HbSS accounts for a substantial share of pediatric transfusion use in Uganda, this high prevalence of adaptive malaria counter-mutations suggests shifting epidemiology regarding the protective effects of the sickle allele.

Alexandra Power-Hays, MD: No relevant conflicts of interest to declare.